BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takemura K, Yuasa T, Inamura K, Amori G, Koga F, Board PG, Yonese J. Impact of Serum γ-Glutamyltransferase on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy. Target Oncol 2020;15:347-56. [PMID: 32474759 DOI: 10.1007/s11523-020-00719-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Han Y, Park IS, Kim SI, Wang W, Yoo J, Jo H, Lee J, Seol A, Han KD, Song YS. Increasing serum gamma-glutamyltransferase level accompanies a rapid increase in the incidence of endometrial cancer in Korea: A nationwide cohort study. Gynecol Oncol 2021;161:864-70. [PMID: 33795129 DOI: 10.1016/j.ygyno.2021.03.024] [Reference Citation Analysis]
2 Une M, Takemura K, Inamura K, Fukushima H, Ito M, Kobayashi S, Yuasa T, Yonese J, Board PG, Koga F. Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel. Cancers (Basel) 2021;13:5587. [PMID: 34771748 DOI: 10.3390/cancers13215587] [Reference Citation Analysis]
3 Velaer K, Thomas IC, Yang J, Kapphahn K, Metzner TJ, Golla A, Hoerner CR, Fan AC, Master V, Chertow GM, Brooks JD, Patel CJ, Desai M, Leppert JT. Clinical laboratory tests associated with survival in patients with metastatic renal cell carcinoma: A Laboratory Wide Association Study (LWAS). Urol Oncol 2021:S1078-1439(21)00374-4. [PMID: 34580027 DOI: 10.1016/j.urolonc.2021.08.011] [Reference Citation Analysis]
4 Takemura K, Board PG, Koga F. A Systematic Review of Serum γ-Glutamyltransferase as a Prognostic Biomarker in Patients with Genitourinary Cancer. Antioxidants (Basel) 2021;10:549. [PMID: 33916150 DOI: 10.3390/antiox10040549] [Reference Citation Analysis]
5 Yoshino M, Ishihara H, Ishiyama Y, Tachibana H, Toki D, Yamashita K, Kobayashi H, Fukuda H, Yoshida K, Takagi T, Iizuka J, Ishida H, Kondo T, Tanabe K. Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Marker of Nivolumab Monotherapy for Previously Treated Metastatic Renal Cell Carcinoma. In Vivo 2021;35:2855-62. [PMID: 34410978 DOI: 10.21873/invivo.12573] [Reference Citation Analysis]